Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357617 | 0.86 | FFAR4 (0.48) | CHRM4FFAR4FFAR1 | |
| SCHEMBL1024488 | 0.85 | KDM4E (0.53) | CHRM4FFAR4FFAR1DRD2 | |
| SCHEMBL1026537 | 0.84 | GAA (0.41) | CHRM4FFAR4FFAR1 | |
| SCHEMBL1025401 | 0.84 | GAA (0.56) | CHRM4FFAR4FFAR1DRD3 | |
| SCHEMBL4359206 | 0.84 | DPP4 (0.43) | CHRM4FFAR4FFAR1C5AR1 | |
| SCHEMBL1023731 | 0.84 | KDM4E (0.55) | DRD2 | |
| Trifluoroacetic Acid SCHEMBL1024810 | 0.82 | FFAR4 (0.55) | CHRM4FFAR4FFAR1C5AR1DRD4 | |
| SCHEMBL1022983 | 0.82 | GRM2 (0.44) | FFAR4DRD4DRD2DRD3THRB | |
| SCHEMBL1024922 | 0.81 | CHRM2 (0.46) | CHRM4FFAR4FFAR1 | |
| SCHEMBL4364982 | 0.81 | CHRM4 (0.46) | CHRM4FFAR4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CHRM4 4834/4885FFAR4 2075/4885FFAR1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.